Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2022-03-27 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-03-27 English
(1) PROPOSED ADOPTION OF THE 2022 A SHARE INCENTIVE SCHEME AND THE ASSESSMENT MANAGEMENT MEASURES&#x3b; (2) PROPOSED ISSUE AND GRANT OF THE NEW A SHARES UNDER THE 2022 A SHARE INCENTIVE SCHEME PURSUAN
AGM Information Classification · 95% confidence The document is an announcement regarding the proposed adoption of a 2022 A Share Incentive Scheme by Pharmaron Beijing Co., Ltd. It details the scheme's purpose, participants, grant price, allocation, and other related matters. The announcement mentions that the scheme is subject to approval at the upcoming Annual General Meeting (AGM) and that a circular containing further details and a notice of the AGM will be sent to shareholders. The content focuses on corporate governance, share incentive plans, and shareholder meeting proposals rather than financial results or regulatory certifications. It is not a full financial report, audit report, or earnings release. It is also not a voting result declaration or a proxy solicitation but rather an announcement of proposals to be considered at the AGM. Given the detailed nature of the proposal and its connection to the AGM, this document fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related to it.
2022-03-27 English
CONNECTED TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN ANIKEEPER
M&A Activity Classification · 95% confidence The document is an announcement by Pharmaron Beijing Co., Ltd. regarding the acquisition of 100% equity interest in Anikeeper. It details the acquisition agreement, consideration, conditions precedent, completion date, and implications under the Hong Kong Stock Exchange Listing Rules. The document is focused on a transaction involving the purchase of a subsidiary, including financial details and regulatory compliance related to connected transactions. There is no indication that this is a full annual or interim report, audit report, earnings release, or other financial report. Instead, it is a corporate announcement about a merger and acquisition activity. Therefore, the document fits the category of M&A Activity (Code: TAR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-03-27 English
FINAL DIVIDEND IN BONUS SHARES FOR THE YEAR ENDED DECEMBER 31, 2021
Notice of Dividend Amount Classification · 95% confidence The document is an announcement titled 'FINAL DIVIDEND IN BONUS SHARES FOR THE YEAR ENDED DECEMBER 31, 2021' by Pharmaron Beijing Co., Ltd. It provides details about a bonus issue of shares as a dividend, including distribution ratio, dates to be announced, and share registrar information. The document is relatively short (3090 characters) and structured as an announcement rather than a full report. It does not contain financial statements or detailed financial analysis. The content fits the description of a Notice of Dividend Amount (DIV), which announces dividend amounts and related shareholder information. Therefore, the appropriate classification is DIV with high confidence.
2022-03-27 English
FINAL DIVIDEND IN CASH FOR THE YEAR ENDED DECEMBER 31, 2021
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Cash Dividend Announcement for Equity Issuer' and provides detailed information about the final dividend for the year ended December 31, 2021, including dividend amount, withholding tax details, and related shareholder information. It does not contain financial statements or comprehensive financial performance data but focuses solely on dividend declaration details. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and shareholder details. The document length is 5710 characters, sufficient to provide detailed dividend information but not a full financial report. Therefore, the appropriate classification is DIV.
2022-03-27 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021' and contains detailed consolidated financial statements including profit or loss, comprehensive income, financial position, and notes to the consolidated financial statements. It includes extensive financial data for the full fiscal year 2021 with comparative figures for 2020. The presence of comprehensive financial statements and detailed notes indicates this is a full annual report rather than a brief announcement or summary. The document length is 15,000 characters, which supports it being a full report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-03-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.